Tenderwize
Zurück zur Suche

Open House Originale Agreement for Vericiguat

Techniker Krankenkasse·Hamburg, Germany·Deadline Sep 29, 2027 · 401 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-24 - Vericiguat

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Offers/contracts cannot be submitted via the portal; the notice says portal submission is technically not possible and...

Participation is limited to pharmaceutical undertakings with the required AMG status, seat location, authorisation, and...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Supply/rebate agreement for pharmaceutical products, specifically the active substance Vericiguat.
  • Open House arrangement with uniform contractual conditions for all eligible participants.
Vollständige Zusammenfassung anzeigen

This is a German Open House supply arrangement for Vericiguat (CPV 33600000 Pharmaceutical products) led by Techniker Krankenkasse, with hkk and HEK listed as participating buyers. It is not a classic competitive award procedure: all eligible pharmaceutical companies meeting the stated conditions may join during the contract period, with no exclusivity and no individual negotiations. The contract term is up to 24 months from 01.10.2025 to 30.09.2027, with automatic earlier end if patent/market exclusivity expires. No contract value is stated. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post, and the procurement documents are available electronically but were not analyzed in extracted text beyond the notice.

Risiken

Offers/contracts cannot be submitted via the portal; the notice says portal submission is technically not possible and...

Participation is limited to pharmaceutical undertakings with the required AMG status, seat location, authorisation, and...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the relevant medicinal product.
  • Applicant must have its seat in Germany, another EU Member State, or an EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product and/or otherwise be entitled to place it on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Originale Agreement for Vericiguat

Open House supply arrangement for the active substance Vericiguat. The notice states that all suitable pharmaceutical companies may conclude a rebate agreement under Section 130c(1) SGB V. No exclusivity, no individual negotiations, and uniform conditions apply. The lot is nationwide in Germany.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Sep 2025 - Sep 2027

Kategorie

Pharmaceutical products

Frist

Deadline Sep 29, 2027

Vergabedetails

Veröffentlichungsdatum
18 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
540042-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3